Skip to content

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Intensity-Modulated Stereotactic Radiotherapy as an Upfront Scalp-Sparing Intervention for the Treatment of Newly Diagnosed Grade II-IV Gliomas

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03251027
Enrollment
100
Registered
2017-08-16
Start date
2017-07-17
Completion date
2027-12-31
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma

Brief summary

This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

Detailed description

PRIMARY OBJECTIVES: I. To determine the effect of intensity-modulated (IM)-stereotactic radiotherapy (SRT) on the incidence of wound infection (requiring oral/intravenous \[IV\] antibiotics or surgery), or wound dehiscence. SECONDARY OBJECTIVES: I. To determine the effect of IM-SRT on the incidence of titanium implants as palpable cranial defects due to scalp thinning. II. To determine the effect of IM-SRT on the incidence of hair loss and recovery rate. III. To determine the effect on quality of life (QoL) using European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L). TERTIARY OBJECTIVES: I. To determine if treatment of Intensity-modulated stereotactic radiotherapy (IM-SRT) in patients with newly diagnosed grade II-IV gliomas can decrease the loss of scalp thickness in the coronal plane in T-1W magnetic resonance (MR) images.

Interventions

RADIATIONIntensity-Modulated Radiation Therapy

Undergo IM-SRT

Ancillary studies

Sponsors

Sidney Kimmel Cancer Center at Thomas Jefferson University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must have histologically confirmed low or high grade glioma (grade II-IV) * Karnofsky performance status (KPS) \>= 60 * Patients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment * Estimated survival \>= 3 months * Labs considered acceptable per standard of care * Patient must sign a study specific informed consent form * Radiation treatment must begin \>= 3 weeks and =\< 8 weeks after surgery

Exclusion criteria

* Prior history of scalp radiation or intolerance to standard course of radiation treatment * Co-morbidities that would influence wound healing including diabetes (insulin dependent) or smoking (current ongoing use) * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * Karnofsky performance status (KPS) \< 60 * Patient can't have magnetic resonance imaging (MRI) scan * Active collagen vascular disease

Design outcomes

Primary

MeasureTime frameDescription
Incidence of wound infection or wound dehiscenceUp to 2 yearsWill assess the impact of intensity-modulated stereotactic radiotherapy (IM-SRT) on the incidence of wound infection, or wound dehiscence.

Secondary

MeasureTime frameDescription
Incidence of titanium implantsUp to 2 yearsWill the impact of IM-SRT on the incidence of titanium implants as palpable cranial defects due to scalp thinning. Rates of titanium implant discomfort will be summarized by cohort with exact 95% confidence intervals. Within-cohort changes will be estimated using linear contrasts of model parameters.
Incidence of hair lossUp to 2 yearsWill assess the impact of IM-SRT on the incidence of hair loss. Will be summarized by cohort with exact 95% confidence intervals. Within-cohort changes will be estimated using linear contrasts of model parameters.
Incidence of recovery rateUp to 2 yearsWill assess the impact of IM-SRT on the incidence of recovery rate. Will be summarized by cohort with exact 95% confidence intervals. Within-cohort changes will be estimated using linear contrasts of model parameters.
Quality of life using European Quality of Life Five Dimension Five Level Scale QuestionnaireUp to 2 yearsWill assess the impact on quality of life using European Quality of Life Five Dimension Five Level Scale Questionnaire. Will be modeled using mixed effects linear regression. Within-cohort changes will be estimated using linear contrasts of model parameters.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORWenyin Shi, MD

Thomas Jefferson University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026